CN101766569B - 一种长效抗菌药物油乳剂及其制备方法 - Google Patents
一种长效抗菌药物油乳剂及其制备方法 Download PDFInfo
- Publication number
- CN101766569B CN101766569B CN2010101133939A CN201010113393A CN101766569B CN 101766569 B CN101766569 B CN 101766569B CN 2010101133939 A CN2010101133939 A CN 2010101133939A CN 201010113393 A CN201010113393 A CN 201010113393A CN 101766569 B CN101766569 B CN 101766569B
- Authority
- CN
- China
- Prior art keywords
- oil
- water
- oil phase
- emulsion
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 149
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 18
- 238000004945 emulsification Methods 0.000 title description 2
- 239000012071 phase Substances 0.000 claims abstract description 65
- 239000002552 dosage form Substances 0.000 claims abstract description 21
- 239000003381 stabilizer Substances 0.000 claims abstract description 21
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims abstract description 15
- 239000008346 aqueous phase Substances 0.000 claims abstract description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 15
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 15
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 230000000844 anti-bacterial effect Effects 0.000 claims description 56
- 229940088710 antibiotic agent Drugs 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 8
- 239000007766 cera flava Substances 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 8
- 229940124350 antibacterial drug Drugs 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229960001082 trimethoprim Drugs 0.000 claims description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 57
- 229940079593 drug Drugs 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000003912 environmental pollution Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 115
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Natural products C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 111
- 150000001875 compounds Chemical class 0.000 description 110
- 229940090044 injection Drugs 0.000 description 84
- 238000002347 injection Methods 0.000 description 84
- 239000007924 injection Substances 0.000 description 84
- 239000003921 oil Substances 0.000 description 81
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 64
- 229960000740 enrofloxacin Drugs 0.000 description 64
- 229960003405 ciprofloxacin Drugs 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 37
- 241000894006 Bacteria Species 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 28
- 238000000034 method Methods 0.000 description 28
- 241000283973 Oryctolagus cuniculus Species 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 230000002949 hemolytic effect Effects 0.000 description 22
- 230000007794 irritation Effects 0.000 description 22
- 229940020010 ciprofloxacin injection Drugs 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 230000009471 action Effects 0.000 description 17
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 241000700199 Cavia porcellus Species 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 14
- 230000034994 death Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000008588 hemolysis Effects 0.000 description 14
- 230000003387 muscular Effects 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- 206010002198 Anaphylactic reaction Diseases 0.000 description 12
- 238000011047 acute toxicity test Methods 0.000 description 12
- 208000003455 anaphylaxis Diseases 0.000 description 12
- IIZVTUWSIKTFKO-UHFFFAOYSA-N 2-hydroxypropanoic acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound CC(O)C(O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IIZVTUWSIKTFKO-UHFFFAOYSA-N 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 10
- 231100000111 LD50 Toxicity 0.000 description 10
- 230000036783 anaphylactic response Effects 0.000 description 10
- 230000036760 body temperature Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 229960001937 trimethoprim lactate Drugs 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000010255 intramuscular injection Methods 0.000 description 9
- 239000007927 intramuscular injection Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 description 7
- 241000607142 Salmonella Species 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229960004055 ciprofloxacin lactate Drugs 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 206010034107 Pasteurella infections Diseases 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000005485 electric heating Methods 0.000 description 6
- 230000001408 fungistatic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 201000005115 pasteurellosis Diseases 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000273 veterinary drug Substances 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000008354 sodium chloride injection Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940051027 pasteurella multocida Drugs 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 101100243764 Caenorhabditis elegans phb-1 gene Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000194046 Streptococcus intermedius Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 ciprofloxacin compound Chemical class 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 208000020470 nervous system symptom Diseases 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008251 pharmaceutical emulsion Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 108010035947 CPLX inhibitor Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101133939A CN101766569B (zh) | 2010-02-24 | 2010-02-24 | 一种长效抗菌药物油乳剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101133939A CN101766569B (zh) | 2010-02-24 | 2010-02-24 | 一种长效抗菌药物油乳剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101766569A CN101766569A (zh) | 2010-07-07 |
CN101766569B true CN101766569B (zh) | 2011-12-28 |
Family
ID=42499770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101133939A Expired - Fee Related CN101766569B (zh) | 2010-02-24 | 2010-02-24 | 一种长效抗菌药物油乳剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101766569B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102415991B (zh) * | 2011-11-24 | 2013-05-01 | 陈鹏举 | 恩诺沙星长效注射液及其制备方法 |
CN102727434A (zh) * | 2012-06-26 | 2012-10-17 | 格特生物制药(天津)有限公司 | 一种兽用恩诺沙星纳米乳液 |
CN114042100B (zh) * | 2021-10-28 | 2023-05-02 | 湖南农业大学 | 含中药提取物的抗菌组合物及其应用 |
-
2010
- 2010-02-24 CN CN2010101133939A patent/CN101766569B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101766569A (zh) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703469B (zh) | 甲磺酸达氟沙星脂质体的制备方法及其产品 | |
CN101766569B (zh) | 一种长效抗菌药物油乳剂及其制备方法 | |
CN102119923B (zh) | 一种兽用抗菌油、水双混悬型注射用乳剂及其制备方法 | |
CN102397237B (zh) | 一种替米考星胶束制剂及其制备方法 | |
CN103417478B (zh) | 一种以水为基质的伊维菌素o/w型注射液及其制备方法 | |
CN103222978B (zh) | 复方磺胺甲噁唑注射液及制备方法 | |
CN103006617B (zh) | 一种癸氧喹酯口服微囊制剂及其制备工艺 | |
CN101982173A (zh) | 适用于畜禽的甲磺酸达氟沙星-阿莫西林混悬注射液及其制备与应用 | |
CN102614112A (zh) | 一种盐酸洛美沙星乳膏及其制备方法 | |
CN103211818B (zh) | 一种治疗或预防家畜细菌性和支原体疾病的药物组合物及其用途 | |
CN106362139B (zh) | 一种长效土霉素注射液及其制备方法 | |
CN106943349A (zh) | 一种泰地罗新混悬注射液及其制备方法 | |
CN104906039A (zh) | 一种替米考星注射用混悬剂及其制备方法 | |
CN108403631A (zh) | 酒石酸泰万菌素油混悬注射剂及其制备方法 | |
CN101361709B (zh) | 一种长效恩诺沙星注射液及其制备方法 | |
CN107875154B (zh) | 含有哌拉西林的组合物、其药物制剂及其应用 | |
CN101879171A (zh) | 一种防治鸡白冠病口服液及其制备方法 | |
CN101574355A (zh) | 一种兽用复方抗菌注射液及其制备方法 | |
CN103690544A (zh) | 头孢喹肟原料及其制剂在制备治疗禽抗菌药物中的应用 | |
CN1706391A (zh) | 土霉素混悬乳剂 | |
CN101889979A (zh) | 一种犬用伊曲康唑注射液及其制备方法 | |
CN104610281B (zh) | 头孢噻呋镁及其制备和使用方法 | |
CN103585318B (zh) | 一种盐酸左氧氟沙星复合脂质体及制备方法 | |
CN101933927A (zh) | 一种含恩诺沙星六水合物组合物及其在制备治疗或预防家畜疾病的药物中的应用 | |
CN102028704B (zh) | 一种兽用酵母葡聚糖注射液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HU'NAN BIOLOGICAL VETERINARY MEDICINE CO., LTD. Free format text: FORMER OWNER: AGRICULTURAL UNIVERSITY OF HU'NAN Effective date: 20121102 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Dong Wei Inventor after: Li Xiaowen Inventor after: Sun Zhiliang Inventor after: Tan Wugui Inventor after: Cai Hao Inventor before: Dong Wei Inventor before: Li Xiaowen Inventor before: Sun Zhiliang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410128 CHANGSHA, HUNAN PROVINCE TO: 410205 CHANGSHA, HUNAN PROVINCE Free format text: CORRECT: INVENTOR; FROM: DONG WEI LI XIAOWEN SUN ZHILIANG TO: DONG WEI LI XIAOWEN SUN ZHILIANG TAN WUGUI CAI HAO |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121102 Address after: 410205 Hunan province Changsha hi tech Development Zone, Lu Valley Lulong Road No. 199 building 1403 room A mark Lugu coordinates Patentee after: HUNAN TAIGU BIOTECHNOLOGY CO.,LTD. Address before: 410128 Hunan province Changsha Furong District Agricultural Road No. 1 Hunan Agricultural University Patentee before: Hunan Agricultural University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210326 Address after: Room 310-3, headquarters building, Changsha Zhongdian Software Park Co., Ltd., No. 39, Jianshan Road, Changsha hi tech Development Zone, Changsha, Hunan 410000 Patentee after: Hunan Huigu Agricultural Ecology Research Institute Co.,Ltd. Address before: Room 1403, building a, Lugu coordinate, No. 199, Lugu Lulong Road, high tech Development Zone, Changsha City, Hunan Province, 410205 Patentee before: HUNAN TAIGU BIOTECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 |
|
CF01 | Termination of patent right due to non-payment of annual fee |